Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.55 |
| ▸ | F7 | P08709 | 5/20 | 0.55 |
| ▸ | F3 | P13726 | 5/20 | 0.55 |
| ▸ | TERT | O14746 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | FABP4 | P15090 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373181 | 0.93 | PPARG (0.62) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2285676 | 0.89 | PPARG (0.58) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL31373182 | 0.87 | ALDH1A1 (0.66) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL15662569 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL11857561 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL29969963 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL9439470 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL5974158 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL17199787 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL28981818 | 0.87 | EP300 (0.54) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322299-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2021-10-21 | — | — | US | claimed |
| EP-2575807-B1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | NOVAK MAJA (HR) | 2014-02-19 | — | — | EP | claimed |
| CN-1334700-A | Application of preparation in controlling expression of target gene | SINZETA LTD (GB) | 2002-02-06 | — | — | CN | claimed |
| WO-2000044223-A9 | USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE | SYNGENTA LTD (GB) | 2001-11-15 | — | — | WO | claimed |
| EP-1150563-A1 | USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE | Syngenta Limited (GB) | 2001-11-07 | — | — | EP | claimed |
| WO-2000044223-A1 | USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE | SYNGENTA LIMITED (GB) | 2000-08-03 | — | — | WO | claimed |
| EP-0229899-B1 | PAINTS | DESOWAG Materialschutz GmbH (DE) | 1991-07-03 | — | — | EP | claimed |
| US-20220184038-A1 | STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES | SISAF LIMITED (GB) | 2022-06-16 | — | — | US | disclosed |
| EP-2575807-A1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | Novak, Maja (HR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011148203-A1 | FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME | NOVAK MAJA (HR) | 2011-12-01 | — | — | WO | disclosed |
| CN-101048137-A | Spontaneously dispersible pharmaceutical composition | NOVARTIS AG (CH) | 2007-10-03 | — | — | CN | disclosed |
| US-7064108-B2 | Topical ivermectin composition | MERCK & CO., INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050143325-A1 | Topical invermectin composition | SCHERING CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1151120-A1 | INDUCIBLE EXPRESSION SYSTEM FOR USE IN PLANTS | Syngenta Limited (GB) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150563-A1 | USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE | Syngenta Limited (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001009357-A2 | ETHANOL INDUCIBLE EXPRESSION SYSTEM | SYNGENTA LIMITED (GB) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000044223-A1 | USE OF A FORMULATION FOR CONTROLLING EXPRESSION OF A TARGET GENE | SYNGENTA LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044917-A1 | INDUCIBLE EXPRESSION SYSTEM FOR USE IN PLANTS | SYNGENTA LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| US-5877209-A | THE ANTIOXIDANT OR FREE RADICAL BLOCKING AGENT IS ASCORBIC-ACID, BUTYLATED HYDROXYTOLUENE (BHT), BUTYLATED HYDROXYANISOLE (BHA), A MIXTURE OF ASCORBIC ACID AND BHT OR BHA OR A BLEND OF TOCOPHEROLS AND ASCORBIC ACID. | YUNIS ADEL A (US) | 1999-03-02 | — | — | US | disclosed |
| US-5646098-A | Carbonyl containing compounds and their derivatives as multi-functional fuel and lube additives | EXXON CHEMICAL PATENTS INC (US) | 1997-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184038-A1 | STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES | SGMS1, SGMS2, SMURF1 | PPARG 820/4885PPARD 953/4885PPARA 850/4885 |
| US-20050143325-A1 | Topical invermectin composition | DPM1, CAPRIN1, COLGALT1 | PPARG 1550/4885PPARD 2041/4885PPARA 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.